Article
Geriatrics & Gerontology
Yong Hoon Kim, Ae-Young Her, Myung Ho Jeong, Byeong-Keuk Kim, Sung-Jin Hong, Sang-Ho Park, Byung Gyu Kim, Seunghwan Kim, Chul-Min Ahn, Jung-Sun Kim, Young-Guk Ko, Donghoon Choi, Myeong-Ki Hong, Yangsoo Jang
Summary: In older adults with AMI, the 2-year clinical outcomes of patients with prediabetes and T2DM were worse than those with normoglycemia but similar between prediabetes and T2DM. Comparable treatment strategies should be strengthened between prediabetes and T2DM in older adults with AMI.
Article
Medicine, General & Internal
Yong Hoon Kim, Ae-Young Her, Myung Ho Jeong, Byeong-Keuk Kim, Sung-Jin Hong, Seunghwan Kim, Chul-Min Ahn, Jung -Sun Kim, Young-Guk Ko, Donghoon Choi, Myeong-Ki Hong, Yangsoo Jang
Summary: Current smoking has negative effects on the clinical outcomes of prediabetic and AMI patients, highlighting the need for increased attention and more intensive treatment strategies including smoking cessation.
AMERICAN JOURNAL OF THE MEDICAL SCIENCES
(2022)
Article
Cardiac & Cardiovascular Systems
Yong Hoon Kim, Ae-Young Her, Myung Ho Jeong, Byeong-Keuk Kim, Sung-Jin Hong, Seunghwan Kim, Chul-Min Ahn, Jung-Sun Kim, Young-Guk Ko, Donghoon Choi, Myeong-Ki Hong, Yangsoo Jang
Summary: This study found that patients with prediabetes and T2DM in AMI patients have similar long-term clinical outcomes after receiving statin treatment. The results of high-intensity and low-moderate-intensity statin treatments were also similar. In patients enrolled after October 2012, high-intensity statin users had significantly lower rates of MACE and repeat revascularization compared to low-moderate intensity statin users. The benefits of high-intensity statin therapy over low-moderate-intensity statin therapy were more pronounced in the normoglycemia group.
BMC CARDIOVASCULAR DISORDERS
(2021)
Article
Multidisciplinary Sciences
Yu-Cheng Kao, Tien-Hsing Chen, Chi-Hung Liu, Jawl-Shan Hwang, Ching-Chung Hsiao, Yu-Sheng Lin, Chun-Tai Mao, Ming-Jui Hung, Yan-Rong Li
Summary: In patients with type 2 diabetes mellitus, the study found that Atorvastatin 40 mg and ezetimibe 10 mg/simvastatin 20 mg had similar reductions of low-density lipoprotein cholesterol and major cardiovascular outcomes. However, the Atorvastatin 40 group had lower risks of unstable angina, percutaneous coronary intervention, and coronary artery bypass grafting compared to the ezetimibe/simvastatin group. This suggests that the main driver for cardiovascular risk reductions is still LDL-C lowering.
SCIENTIFIC REPORTS
(2021)
Article
Cardiac & Cardiovascular Systems
Ville Kyto, Paivi Rautava, Aleksi Tornio
Summary: Initiating high-dose statin therapy after myocardial infarction is associated with better long-term cardiovascular outcomes.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY
(2023)
Article
Medicine, General & Internal
Rosemary Brown, Jim Lewsey, Sarah Wild, Jennifer Logue, Paul Welsh
Summary: This study found that non-achievement of lipid and statin adherence targets in myocardial infarction survivors is associated with increased risks of all-cause and cardiovascular disease mortality, but not with recurrent myocardial infarctions. Further research is needed to optimize their use in clinical practice to improve outcomes.
Article
Cardiac & Cardiovascular Systems
Ville Kyto, Antti Saraste, Aleksi Tornio
Summary: This study found that not using statins early after myocardial infarction (MI) is associated with adverse outcomes, including higher all-cause mortality and incidence of cardiovascular events. The lack of statin therapy was associated with increased risk for patients, regardless of other factors such as gender, age, comorbidities, etc.
Article
Pharmacology & Pharmacy
Stella Trompet, Iris Postmus, Helen R. Warren, Raymond Noordam, Roelof A. J. Smit, Elizabeth Theusch, Xiaohui Li, Benoit Arsenault, Daniel I. Chasman, Graham A. Hitman, Patricia B. Munroe, Jerome I. Rotter, Bruce M. Psaty, Mark J. Caulfield, Ron M. Krauss, Adrienne L. Cupples, Wouter J. Jukema
Summary: The pharmacogenetic effect of genetic variation on cardiovascular disease risk reduction in response to statin treatment was investigated through a genome-wide association study (GWAS). The results showed that genetic variation did not significantly affect the response of statins on cardiovascular risk reduction. This suggests that genetic testing for predicting the effects of statins on clinical events may not be a useful tool in clinical practice.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Endocrinology & Metabolism
Volker H. Schmitt, Lukas Hobohm, Thomas Munzel, Philip Wenzel, Tommaso Gori, Karsten Keller
Summary: This study found that diabetic patients have a higher in-hospital mortality rate and a higher recurrent MI rate during acute myocardial infarction (MI) compared to non-diabetic patients. Diabetic patients also had lower rates of coronary artery angiography and interventional revascularization compared to non-diabetic patients.
DIABETES & METABOLISM
(2021)
Article
Endocrinology & Metabolism
Yingting Zuo, Anxin Wang, Shuohua Chen, Xue Tian, Shouling Wu, Yan He
Summary: Analysis of data from a prospective study revealed five distinct eGFR trajectories among individuals with diabetes or prediabetes, and showed an association between eGFR trajectories and the risk of myocardial infarction (MI).
JOURNAL OF DIABETES
(2021)
Article
Cardiac & Cardiovascular Systems
Xuehao Lu, Luming Zhang, Shaojin Li, Dan He, Tao Huang, Hongsheng Lin, Haiyan Yin, Jun Lyu
Summary: This study investigated the effects of statins and non-statins on ICU and in-hospital mortality rates in patients with AMI and diabetes. The results showed that statins can significantly reduce ICU and in-hospital mortality rates in these patients, even in the population without hyperlipidemia.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2022)
Article
Cardiac & Cardiovascular Systems
Jessica Schubert, Bertil Lindahl, Hakan Melhus, Henrik Renlund, Margret Leosdottir, Ali Yari, Peter Ueda, Stefan James, Stephanie R. Reading, Paul J. Dluzniewski, Andrew W. Hamer, Tomas Jernberg, Emil Hagstrom
Summary: Clinical trials have shown that reducing LDL-C can decrease cardiovascular events, and a study found that larger reductions in LDL-C and more intensive statin therapy after myocardial infarction were associated with lower risks of cardiovascular outcomes and all-cause mortality.
EUROPEAN HEART JOURNAL
(2021)
Article
Endocrinology & Metabolism
Side Gao, Wenjian Ma, Sizhuang Huang, Xuze Lin, Mengyue Yu
Summary: The study showed that prediabetes is associated with poor prognosis in patients with MINOCA and has a significant impact on the risk of MACE. These findings highlight the importance of early identification and risk stratification of prediabetes.
DIABETOLOGY & METABOLIC SYNDROME
(2021)
Article
Medicine, General & Internal
Karsten Keller, Volker H. Schmitt, Markus Vosseler, Christoph Brochhausen, Thomas Munzel, Lukas Hobohm, Christine Espinola-Klein
Summary: The study revealed that patients with PAD and DM had a more severe cardiovascular risk profile and higher rates of in-hospital mortality, major adverse cardiovascular and cerebrovascular events, and amputation surgeries.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Cardiac & Cardiovascular Systems
Vardhmaan Jain, Arman Qamar, Kunihiro Matsushita, Muthiah Vaduganathan, Kellan E. Ashley, Muhammad Shahzeb Khan, Deepak L. Bhatt, Sameer Arora, Melissa C. Caughey
Summary: Diabetes is associated with a higher risk of death in patients hospitalized with acute myocardial infarction (AMI), with increasing prevalence of diabetes over time. Patients with diabetes were older, more often Black, and more commonly women. They had higher comorbidities and presented differently compared to patients without diabetes. They also had lower probabilities of receiving certain therapies and higher 1-year mortality risk.
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2023)
Article
Peripheral Vascular Disease
Yong Hoon Kim, Ae-Young Her, Myung Ho Jeong, Byeong-Keuk Kim, Sung-Jin Hong, Sang-Ho Park, Seunghwan Kim, Byung Gyu Kim, Chul-Min Ahn, Jung-Sun Kim, Young-Guk Ko, Donghoon Choi, Myeong-Ki Hong, Yangsoo Jang
Summary: This retrospective cohort study investigated the effects of hypertension on long-term outcomes in AMI patients with different glycemic statuses after implantation of newer-generation drug-eluting stents. The results showed that the major outcomes were similar between the normoglycemia and prediabetes groups in patients without hypertension, but higher in patients with type 2 diabetes mellitus. In patients with hypertension, the major outcomes were similar between the prediabetes and T2DM groups, but higher than those in the normoglycemia group.
Article
Cardiac & Cardiovascular Systems
Yong-Joon Lee, Jae Young Cho, Seng Chan You, Yong-Ho Lee, Kyeong Ho Yun, Yun-Hyeong Cho, Won-Yong Shin, Sang Wook Im, Woong Chol Kang, Yongwhi Park, Sung Yoon Lee, Seung-Jun Lee, Sung-Jin Hong, Chul-Min Ahn, Byeong-Keuk Kim, Young-Guk Ko, Donghoon Choi, Myeong-Ki Hong, Yangsoo Jang, Jung-Sun Kim
Summary: This study evaluated the effect of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy among patients with diabetes mellitus and atherosclerotic cardiovascular disease. The study found that the combination therapy had similar outcomes in terms of cardiovascular events compared to the monotherapy, but had a higher rate of intolerance-related discontinuation or dose reduction. However, the combination therapy was more effective in achieving lower LDL cholesterol levels.
EUROPEAN HEART JOURNAL
(2023)
Article
Cardiac & Cardiovascular Systems
Francesco Costa, Claudio Montalto, Mattia Branca, Sung-Jin Hong, Hirotoshi Watanabe, Anna Franzone, Pascal Vranckx, Joo-Yong Hahn, Hyeon-Cheol Gwon, Fausto Feres, Yangsoo Jang, Giuseppe De Luca, Elvin Kedhi, Davide Cao, Philippe Gabriel Steg, Deepak L. Bhatt, Gregg W. Stone, Antonio Micari, Stephan Windecker, Takeshi Kimura, Myeong-Ki Hong, Roxana Mehran, Marco Valgimigli
Summary: The study evaluated the impact of an abbreviated dual antiplatelet therapy (DAPT) regimen in high bleeding risk patients after percutaneous coronary intervention (PCI), using existing evidence. It found that a shorter DAPT duration (1-3 months) reduced bleeding and cardiovascular mortality without increasing ischemic events in these patients.
EUROPEAN HEART JOURNAL
(2023)
Article
Cardiac & Cardiovascular Systems
Soohyung Park, Seung-Woon Rha, Byoung Geol Choi, Jang Hyun Cho, Sang Ho Park, Jin Bae Lee, Yong Hoon Kim, Sang Min Park, Jae Woong Choi, Ji Young Park, Eun-Seok Shin, Jae Beom Lee, Jon Suh, Jei Keon Chae, Young Jin Choi, Myung Ho Jeong, Kwang Soo Cha, Seung Wook Lee, Ung Kim, Gi Chang Kim, Woong-Gil Choi, Yun-Hyeong Cho, Deok-kyu Cho, Jihun Ahn, Soon-Yong Suh, Se Yeon Choi, Jae Kyeong Byun, Jin Ah Cha, Soo Jin Hyun, Ji Bak Kim, Cheol Ung Choi, Chang Gyu Park
Summary: This study compared the clinical outcomes of immediate and staged complete revascularization in patients with ST-segment elevation myocardial infarction and multivessel disease. The study found that the incidence of major adverse cardiovascular events was slightly higher in the immediate revascularization group compared to the staged revascularization group at 1-year follow-up. However, there were no significant differences in other clinical outcomes between the two groups. The study suggests that further large randomized clinical trials are needed to determine the optimal timing of complete revascularization for these patients.
AMERICAN HEART JOURNAL
(2023)
Article
Hematology
Bom Lee, Seung-Jun Lee, Byeong-Keuk Kim, Yong-Joon Lee, Sung-Jin Hong, Chul-Min Ahn, Jung-Sun Kim, Young-Guk Ko, Donghoon Choi, Meyong-Ki Hong, Yangsoo Jang
Summary: This study examined the impact of sex differences on clinical outcomes in patients with acute coronary syndrome treated with ticagrelor monotherapy after either 3-month or 12-month dual-antiplatelet therapy. The results showed that women had a higher risk of adverse clinical events, major adverse cardiac and cerebrovascular events, and major bleeding compared to men. However, ticagrelor monotherapy after 3-month dual-antiplatelet therapy was associated with a significantly lower risk of adverse clinical events in women.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
(2023)
Editorial Material
Cardiac & Cardiovascular Systems
Jooyeon Lee, Jung Sun Kim, Chi Young Shim
EUROPEAN HEART JOURNAL
(2023)
Article
Cardiac & Cardiovascular Systems
Seung Hun Lee, Young-Hoon Jeong, David Hong, Ki Hong Choi, Joo Myung Lee, Taek Kyu Park, Jeong Hoon Yang, Joo-Yong Hahn, Seung-Hyuck Choi, Hyeon-Cheol Gwon, Myung Ho Jeong, Byeong-Keuk Kim, Hyung Joon Joo, Kiyuk Chang, Yongwhi Park, Sung Gyun Ahn, Jung-Won Suh, Sang Yeub Lee, Jung Rae Cho, Ae-Young Her, Hyo-Soo Kim, Moo Hyun Kim, Do-Sun Lim, Eun-Seok Shin, Young Bin Song
Summary: This study investigated the long-term outcomes of patients undergoing clopidogrel-based antiplatelet therapy after drug-eluting stent implantation according to CYP2C19 genotypes. The results showed that intermediate metabolizers (IMs) and poor metabolizers (PMs) had an increased risk of the primary outcome compared to rapid metabolizers (RMs) or normal metabolizers (NMs), especially in the first year. The prognostic implication of being an IM or PM was significant in patients with acute coronary syndrome but not in those with stable angina.
JACC-CARDIOVASCULAR INTERVENTIONS
(2023)
Article
Medicine, General & Internal
Sung-Jin Hong, Yong-Joon Lee, Seung-Jun Lee, Bum-Kee Hong, Woong Chol Kang, Jong-Young Lee, Jin-Bae Lee, Tae-Hyun Yang, Junghan Yoon, Chul-Min Ahn, Jung-Sun Kim, Byeong-Keuk Kim, Young-Guk Ko, Donghoon Choi, Yangsoo Jang, Myeong-Ki Hong
Summary: This study compared the effectiveness of initial statin treatment with high-intensity statins versus a treat-to-target strategy in patients with coronary artery disease. The results showed that the treat-to-target strategy of achieving an LDL-C level between 50 and 70 mg/dL was noninferior to high-intensity statin therapy in terms of clinical outcomes over a 3-year period.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2023)
Article
Cardiac & Cardiovascular Systems
Felice Gragnano, Roxana Mehran, Mattia Branca, Anna Franzone, Usman Baber, Yangsoo Jang, Takeshi Kimura, Joo-Yong Hahn, Qiang Zhao, Stephan Windecker, Charles M. Gibson, Byeong-Keuk Kim, Hirotoshi Watanabe, Young Bin Song, Yunpeng Zhu, Pascal Vranckx, Shamir Mehta, Sung-Jin Hong, Kenji Ando, Hyeon-Cheol Gwon, Paolo Calabro, Patrick W. Serruys, George D. Dangas, Eugene P. McFadden, Dominick J. Angiolillo, Dik Heg, Marco Valgimigli
Summary: This study suggests that P2Y12 inhibitor monotherapy after complex percutaneous coronary intervention (PCI) can preserve ischemic protection while limiting bleeding risk. Compared with dual antiplatelet therapy (DAPT), P2Y12 inhibitor monotherapy after 1-month to 3-month DAPT can reduce the major bleeding risk in complex PCI patients.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2023)
Article
Medicine, General & Internal
Jong -Il Park, Seung-Jun Lee, Bum-Kee Hong, Yun-Hyeong Cho, Won-Yong Shin, Sang-Wook Lim, Woong-Chol Kang, Yongwhi Park, Sung-Yoon Lee, Yong-Joon Lee, Sung-Jin Hong, Chul-Min Ahn, Byeong-Keuk Kim, Young-Guk Ko, Donghoon Choi, Myeong-Ki Hong, Yangsoo Jang, Jung-Sun Kim
Summary: This study analyzed the effects of ezetimibe combination therapy with moderate-intensity statins in patients with atherosclerotic cardiovascular disease following percutaneous coronary intervention. The results showed that the combination therapy did not increase the risk of cardiovascular events and was effective in reducing low-density lipoprotein cholesterol levels.
Article
Cardiac & Cardiovascular Systems
Jong-Il Park, Seung-Jun Lee, Young-Joon Hong, Sang-Yong Yoo, Yong-Sung Seo, Eui Im, Jong-Kwan Park, Jin-Bae Lee, Yong-Joon Lee, Sung-Jin Hong, Chul-Min Ahn, Jung-Sun Kim, Young-Guk Ko, Donghoon Choi, Myeong-Ki Hong, Byeong-Keuk Kim
Summary: This study investigated the 12-month clinical outcomes of older patients who underwent Synergy everolimus-eluting stent (S-EES) implantation. The results showed favorable device-related outcomes in older patients, regardless of the presence of ischemic risks. However, older patients with high ischemic risks had worse clinical outcomes.
AMERICAN JOURNAL OF CARDIOLOGY
(2023)
Article
Cardiac & Cardiovascular Systems
Seung-Jun Lee, Hyeok-Hee Lee, Young-Guk Ko, Chul-Min Ahn, Yong-Joon Lee, Jung-Sun Kim, Byeong-Keuk Kim, Myeong-Ki Hong, Hyeon Chang Kim, Cheol Woong Yu, Jae-Hwan Lee, Seung-Whan Lee, Young Jin Youn, Jong Kwan Park, Chang-Hwan Yoon, Seung Woon Rha, Pil-Ki Min, Seung-Hyuk Choi, In-Ho Chae, K VIS Investigators
Summary: The clinical efficacy of drug-coated balloons (DCBs) and drug-eluting stents (DES) in the treatment of femoropopliteal artery (FPA) disease is limited in real-world practice. Compared to bare-metal stents (BMS), DCBs and DES showed significantly lower incidence of target lesion revascularization (TLR) at 2 years.
JACC-CARDIOVASCULAR INTERVENTIONS
(2023)
Article
Cardiac & Cardiovascular Systems
Seung-Jun Lee, Jae Hong Joo, Sohee Park, Choongki Kim, Dong-Woo Choi, Sung-Jin Hong, Chul-Min Ahn, Jung-Sun Kim, Byeong-Keuk Kim, Young-Guk Ko, Donghoon Choi, Yangsoo Jang, Chung-Mo Nam, Myeong-Ki Hong
Summary: This observational study evaluated the effects of high-intensity statin monotherapy compared with combination therapy (statin plus ezetimibe) in patients after drug-eluting stent implantation. The results showed that combination therapy was associated with lower occurrence of adverse events and better drug compliance.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2023)
Article
Cardiac & Cardiovascular Systems
Seung-Jun Lee, Jung-Joon Cha, Woong Gil Choi, Wang-Soo Lee, Jin-Ok Jeong, Seonghoon Choi, Yoon-Haeng Cho, Woojung Park, Chang-Hwan Yoon, Yong-Joon Lee, Sung-Jin Hong, Chul-Min Ahn, Byeong-Keuk Kim, Young-Guk Ko, Donghoon Choi, Myeong-Ki Hong, Yangsoo Jang, Soon Jun Hong, Jung-Sun Kim
Summary: The study aimed to evaluate the outcomes of a moderate-intensity statin with ezetimibe combination in patients with very high risk (VHR) and non-VHR of atherosclerotic cardiovascular disease (ASCVD). The results showed no significant difference in the primary end point between combination therapy and high-intensity statin monotherapy in both VHR and non-VHR patients. Additionally, the combination therapy group had significantly lower levels of low-density lipoprotein cholesterol (LDL-C) compared to the high-intensity statin group, and was associated with greater changes in LDL-C levels and a higher proportion of patients with LDL-C levels below 70 mg/dL. The discontinuation or dose reduction of lipid-lowering drugs due to intolerance occurred less frequently in the combination therapy group.